HUP9802257A2 - Szelektív béta3 adrenerg agonisták, előállításuk és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

Szelektív béta3 adrenerg agonisták, előállításuk és a vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9802257A2
HUP9802257A2 HU9802257A HUP9802257A HUP9802257A2 HU P9802257 A2 HUP9802257 A2 HU P9802257A2 HU 9802257 A HU9802257 A HU 9802257A HU P9802257 A HUP9802257 A HU P9802257A HU P9802257 A2 HUP9802257 A2 HU P9802257A2
Authority
HU
Hungary
Prior art keywords
compounds
preparing
pharmaceutical compositions
compositions containing
hydrogen atom
Prior art date
Application number
HU9802257A
Other languages
English (en)
Inventor
Michael G. Bell
Thomas A. Crowell
Deborah A. Evrard
Donald P. Matthews
John H. McDonald III.
Christopher J. Rito
Anthony J. Shuker
Mark A. Winter
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP9802257A2 publication Critical patent/HUP9802257A2/hu
Publication of HUP9802257A3 publication Critical patent/HUP9802257A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • C07D213/6432-Phenoxypyridines; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány a II típűsú diabetes és a kövérség kezelésére szőlgálószelektív 3 adrenerg receptőr agőnistákra vőnatkőzik. A találmány tárgya tővábbá eljárás a vegyületek előállítására és avegyületeket taralmazó gyógyszerkészítmények. A találmány szerinti vegyületek az (I) általánős képletteljellemezhetők, ahől R1 jelentése OH, halőgénatőm, SO2NHR2, CO2R2, CONHR2, NHCOR2, -NH(tetszőlegesen helyettesített arilcsőpőrt), CF3 vagy CF2H csőpőrt; R1 jelentése hidrőgénatőm, halőgénatőm, 1-4 szénatőmős alkilcsőpőrt,OH, SO2NHR2, CO2R2, CONHR2, NHCOR2, CF3 vagy CF2H csőpőrt; R2 jelentése hidrőgénatőm, 1-4 szénatőmős alkilcsőpőrt vagyarilcsőpőrt; R3 jelentése hidrőgénatőm vgy 1-4 szénatőmős alkilcsőpőrt; R4 jelentése (a), (b) vagy (c) csőpőrt; X jelentése őxigén- vagy kénatőm. ŕ
HU9802257A 1995-09-21 1996-09-20 Selective beta3 adrenergic agonists, process for preparing them and pharmaceutical compositions containing the said compounds HUP9802257A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US408395P 1995-09-21 1995-09-21

Publications (2)

Publication Number Publication Date
HUP9802257A2 true HUP9802257A2 (hu) 1999-02-01
HUP9802257A3 HUP9802257A3 (en) 1999-04-28

Family

ID=21709054

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802257A HUP9802257A3 (en) 1995-09-21 1996-09-20 Selective beta3 adrenergic agonists, process for preparing them and pharmaceutical compositions containing the said compounds

Country Status (23)

Country Link
EP (1) EP0764632B1 (hu)
JP (1) JPH11513376A (hu)
KR (1) KR19990045727A (hu)
CN (1) CN1202106A (hu)
AT (1) ATE203511T1 (hu)
AU (1) AU715493B2 (hu)
BR (1) BR9610481A (hu)
CA (1) CA2232090A1 (hu)
CZ (1) CZ82198A3 (hu)
DE (1) DE69614057T2 (hu)
DK (1) DK0764632T3 (hu)
EA (1) EA001217B1 (hu)
ES (1) ES2158996T3 (hu)
GR (1) GR3036963T3 (hu)
HU (1) HUP9802257A3 (hu)
IL (1) IL123677A0 (hu)
NO (1) NO981204L (hu)
NZ (1) NZ318712A (hu)
PL (1) PL325865A1 (hu)
PT (1) PT764632E (hu)
SI (1) SI0764632T1 (hu)
TR (1) TR199800521T1 (hu)
WO (1) WO1997010822A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
CA2312849A1 (en) 1997-12-05 1999-06-17 Charles David Jones Selective .beta.3 adrenergic agonists
PE20000415A1 (es) 1998-04-08 2000-05-21 Smithkline Beecham Corp Compuestos calciliticos
AUPP796798A0 (en) * 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2001035947A2 (en) * 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
WO2001036412A1 (en) * 1999-11-15 2001-05-25 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
FR2809725B1 (fr) * 2000-06-06 2004-05-07 Sanofi Synthelabo Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
MXPA04008298A (es) 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
JP7080179B2 (ja) 2016-03-15 2022-06-03 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大に関する方法および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498999A (en) * 1966-04-20 1970-03-03 Bristol Myers Co 1-phenoxy and substituted phenoxy-3-(5-tetrazolyl) propanes
GB1433920A (en) * 1973-10-01 1976-04-28 Ici Ltd Alkanolamine derivatives
US4080471A (en) * 1976-06-25 1978-03-21 Aktiebolaget Hassle Use of substituted isopropylaminopropanols for inducing inotropic effects of the human heart
FR2640969B1 (hu) * 1988-12-23 1991-11-22 Midy Spa
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
EP0627407A1 (fr) * 1993-05-28 1994-12-07 MIDY S.p.A. Acide (7S)-7-[(2R)-2(3-chlorophényl)-2-hydroxyéthylamino]-5,6,7,8-tétrahydronaphtalèn-2-yloxy acétique, ses sels pharmaceutiquement acceptables, à action agoniste bêta-3 adrénergique et compositions pharmaceutiques le contenant
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists

Also Published As

Publication number Publication date
CN1202106A (zh) 1998-12-16
DE69614057T2 (de) 2002-03-14
CZ82198A3 (cs) 1998-07-15
BR9610481A (pt) 1999-05-11
EP0764632A2 (en) 1997-03-26
TR199800521T1 (xx) 1998-06-22
EA199800317A1 (ru) 1998-10-29
EP0764632B1 (en) 2001-07-25
NZ318712A (en) 1999-08-30
AU7077096A (en) 1997-04-09
PT764632E (pt) 2001-12-28
NO981204L (no) 1998-04-17
EA001217B1 (ru) 2000-12-25
AU715493B2 (en) 2000-02-03
SI0764632T1 (en) 2001-12-31
PL325865A1 (en) 1998-08-17
EP0764632A3 (en) 1997-12-10
CA2232090A1 (en) 1997-03-27
ES2158996T3 (es) 2001-09-16
MX9802097A (es) 1998-08-30
NO981204D0 (no) 1998-03-17
ATE203511T1 (de) 2001-08-15
DE69614057D1 (de) 2001-08-30
GR3036963T3 (en) 2002-01-31
DK0764632T3 (da) 2001-09-24
HUP9802257A3 (en) 1999-04-28
IL123677A0 (en) 1998-10-30
WO1997010822A1 (en) 1997-03-27
JPH11513376A (ja) 1999-11-16
KR19990045727A (ko) 1999-06-25

Similar Documents

Publication Publication Date Title
HUP9802257A2 (hu) Szelektív béta3 adrenerg agonisták, előállításuk és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9802814A2 (hu) Szelektív béta3 adrenergiás agonista hatású vegyületek, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
DK116480A (da) Fremgangsmaade til fremstilling af substituerede chromoner
HUP9603389A2 (hu) Eljárás 2-acil-amino-alkohol-származékok előállítására és köztitermékeik
HUP9700992A2 (hu) 3-(Piperid-4-il)-1,2-benzizoxazol- és 3-(piperazin-4-il)-1,2-benzizoxazol-származékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
DE3876813T2 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
ES8304097A1 (es) Un procedimiento para la obtencion de un compuesto de 4(3h- quinazolinona).
HUP9900501A2 (hu) Muszkarin receptor antagonista hatású oxa- és tiadiazolszármazékok, intermedierjeik, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP9801423A2 (hu) Kroménszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények
SE7501365L (hu)
HUP0301885A2 (hu) Eljárás tioétercsoport szulfoxidcsoporttá történż oxidálására
HUP9802393A2 (hu) Benzotiazolonszármazékok, alkalmazásuk, az ezeket tartalmazó gyógyszerkészítmények, eljárás a vegyületek előállítására és intermedierjeik
HUP9904384A2 (hu) Imidazo[1,5-a]pirazin-1,3-dion-származékok, eljárás előállításukra, intermedierjeik
HUP0000524A2 (hu) Eljárás tiazolszármazékok és intermedierjeik előállítására
ATE77818T1 (de) Neue naphthylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung.
HUT34480A (en) Process for preparing new beta-carboline derivatives and pharmaceutical compositions containing thereof
HUP0004565A2 (hu) Szubsztituált krománszármazékok, intermedierjeik és azokat tartalmazó gyógyszerkészítmények
KR860001108A (ko) 페닐-나프티리딘의 제조방법
HUP9702368A2 (hu) 3-(1-/2-Hidroxi-fenil/-1-alkoximino-metil)-dioxazin-származékok és intermedierjeik és eljárás ezek előállítására
ATE48276T1 (de) 1,6-naphthyridin-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel.
HUP0201863A2 (hu) Új morfolinszármazékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
KR880005138A (ko) 신규 화합물들
HUP9802571A2 (hu) Piridin-iminil-1,2-benzizoxazolok és -benzizotiazolok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
ES8308329A1 (es) "un metodo de preparar derivados de oxotienobenzoxepina".